These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 15183340)

  • 21. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
    Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
    Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis.
    Julias JG; Boyer PL; McWilliams MJ; Alvord WG; Hughes SH
    Virology; 2004 Apr; 322(1):13-21. PubMed ID: 15063112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
    J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
    Parkin NT; Gupta S; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 reverse transcriptase inhibitors.
    El Safadi Y; Vivet-Boudou V; Marquet R
    Appl Microbiol Biotechnol; 2007 Jun; 75(4):723-37. PubMed ID: 17370068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
    Gallant JE; Gerondelis PZ; Wainberg MA; Shulman NS; Haubrich RH; St Clair M; Lanier ER; Hellmann NS; Richman DD
    Antivir Ther; 2003 Dec; 8(6):489-506. PubMed ID: 14760883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
    Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
    Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
    Ren J; Stammers DK
    Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.
    Gatanaga H; Hachiya A; Kimura S; Oka S
    Virology; 2006 Jan; 344(2):354-62. PubMed ID: 16219331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.
    Sharma PL; Nurpeisov V; Lee K; Skaggs S; Di San Filippo CA; Schinazi RF
    Virology; 2004 Apr; 321(2):222-34. PubMed ID: 15051383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Essential benefits of nucleoside analogue regimens in failing therapy.
    Geretti AM
    J HIV Ther; 2004 May; 9(2):28-33. PubMed ID: 15238873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
    Wainberg MA; Gu Z; Salomon H; Arts EJ; Kleiman L; Parniak MA; Morin N
    C R Acad Sci III; 1995 Mar; 318(3):315-28. PubMed ID: 7540494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
    Selmi B; Deval J; Boretto J; Canard B
    Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.